JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Volume 18, Number 2, 2008
© Mary Ann Liebert, Inc.
Pp. 157–178
DOI: 10.1089/cap.2007.0041
Psychopharmacology of Aggression in Children
and Adolescents with Autism: A Critical Review of
Efficacy and Tolerability
Mihir S. Parikh, B.Sc.,1 Alexander Kolevzon, M.D.,2,3 and Eric Hollander, M.D.2,3
ABSTRACT
Background: Autism is characterized by a clinical triad of symptoms that affect social, language, and behavioral domains. Aggression and self-injury may be associated symptoms of
autism and can result in significant harm to those affected as well as marked distress for their
families. The precise nature of the relationship between aggressive or self-injurious behavior (SIB) and autism remains unclear and as a result, these symptoms are treated with a broad
range of pharmacological approaches. This review seeks to systematically and critically examine the evidence for the pharmacological management of aggression and SIB in children
with autism spectrum disorders.
Method: The entire PubMed database was searched for English language biomedical articles on clinical trials with medication in autism spectrum disorders. Studies were selected
based on the following inclusion criteria: (1) randomized placebo-controlled trials; (2) a sample population that included children and adolescents; (3) at least one standardized assessment of aggression as a primary outcome measure of the study.
Results: Twenty one trials with 12 medications were identified. Five medications produced
significant improvement as compared to placebo, including tianeptine, methylphenidate,
risperidone, clonidine, and naltrexone. Only risperidone and methylphenidate demonstrate
results that have been replicated across at least two studies.
Conclusions: Although many medications have been studied under placebo-controlled conditions, few produce significant improvement. Additional placebo-controlled trials are needed
to increase the number of therapeutic options available in the treatment of aggression in
autism.
1Mount
Sinai School of Medicine, New York, New York.
of Psychiatry, Mount Sinai School of Medicine, New York, New York.
3Seaver Autism Research Center, Mount Sinai School of Medicine, New York, New York.
2Department
157
158
PARIKH ET AL.
INTRODUCTION
A
UTISM IS A DEBILITATING NEURODEVELOPMEN-
TAL DISORDER characterized by impairments in social, language, and behavioral domains. Yet, limited pharmacological options
exist to treat either core symptom domains or
associated psychopathology reliably. Aggression and self-injurious behavior (SIB) are
among the manifestations of behavioral impairment in autism and are often the cause for
emergent psychiatric referral. When present,
aggression and SIB may be both dangerous and
distressing for affected children and their families. Many medications have been studied in
an effort to identify safe and efficacious interventions in children with autism. A number of
reviews have been published that interpret and
synthesize the current findings (King 2000;
Barnard et al. 2002; Hollander et al. 2003a; McDougle et al. 2003; Aman 2004; Rappaport and
Thomas 2004; Findling 2005; Malone et al. 2005;
Kolevzon et al. 2006). Beyond harm reduction,
the effective pharmacological management of
associated symptoms may also improve response rates to behavioral and educational interventions in autism (Audenaert et al. 2001;
McDougle et al. 2003; Findling 2005; Malone et
al. 2005). Issues revolving around medication
tolerability also warrant careful consideration
in this vulnerable, developmentally disabled
population (Harris 1996; Hollander et al.
2003a). The prevalence and impact of aggression and SIB in autism particularly warrants
the need for a systematic review of medication
efficacy and tolerability for these symptoms.
Given the dearth of available pharmacological
treatment in autism, and in light of recent controversy surrounding the use of medication in
children and adolescents, the following review
will critically examine all randomized controlled clinical trials (RCTs) that have examined
the treatment of aggression and SIB in children
and adolescents with autism and autism spectrum disorders.
The etiology of aggression and SIB remains
unclear and is likely heterogeneous in nature
(Rothenberger 1993; King 2000; Rappaport and
Thomas 2004; Findling 2005). However, various mechanisms have been proposed to underlie the presence of these symptoms in
autism, and numerous targets for pharmacological intervention have been suggested.
These targets include the dopaminergic, serotonergic, adrenergic, and opioid systems,
among others. Due to the diversity of hypothesized targets, the following section will review
these mechanisms in further detail.
Several studies support an association between the dopaminergic system and aggression (Ferrari et al. 2003; Retz et al. 2003;
Hoglund et al. 2005). Most animal models of
self-injury suggest dysregulation of dopamine
activity or dopamine receptor hypersensitivity
as etiological factors (Rothenberger 1993). Dopamine dysregulation has also been implicated
in self-injurious patients with autism (Shea et
al. 2004), Lesch-Nyhan (Stodgell et al. 1998),
and Tourette syndrome (Sandyk and Bamford
1987). This association has galvanized clinical
trials with antipsychotic medications, most of
which act as dopaminergic antagonists and
may prevent the onset and maintenance of
aggression and SIB (King 2000). In fact, the
second-generation antipsychotic medication
risperidone is the only agent specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritability,
including aggression and self-injury, in children with autism (Food and Drug Administration 2006). Psychostimulant medications, on
the other hand, are potent dopaminergic agonists and have also been examined in the treatment of aggressive children with autism. This
apparent discrepancy between the use of both
dopaminergic agonists and antagonists in the
treatment of aggressive behavior in children
with autism has not yet been fully reconciled.
However, stimulant medications increase the
availability of dopamine in the striatum, likely
enhancing prefrontal cortical function though
striatal-frontal pathways (Berridge et al. 2006)
and improving inhibitory control. Antipsychotic medications, on the other hand, block
dopamine receptor binding in the mesolimbic
system (Stockton and Rasmussen 1996). Both
classes of medications, despite differing mechanisms of action, may produce a final common
effect in reducing aggression and impulsivity.
Central nervous system regulation of serotonin has also been implicated in aggressive behavior, and several studies have established an
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
association between serotonin depletion and
aggression in both human (Halperin et al. 2006)
and animal models (Vergnes et al. 1988; Johansson et al. 1999). Work that specifically examines the association between serotonergic
regulation and autism dates back to 1961, when
Schain and Freedman (1961) first reported elevated levels of whole-blood serotonin in a subgroup of individuals with autism. Since then,
most investigators have found that peripheral
serotonin levels are significantly higher in subjects with autism as compared to normal controls (Ritvo et al. 1970; Takahashi et al. 1976;
Anderson et al. 1987; Cook et al. 1990; Leventhal et al. 1990; Leboyer et al. 1999), and approximately one third of individuals with
autism are considered to have hyperserotonemia (Hanley et al. 1977). In addition, worsening of autistic symptomatology has been demonstrated following acute depletion of dietary
tryptophan (McDougle et al. 1996a). Selective
serotonin reuptake inhibitors (SSRIs) are
known to impact levels of peripheral and central serotonin, and if serotonin regulation is impaired in autism, it is possible that serotonergic medications may affect the dysregulation
and ameliorate associated symptoms such as
aggression and self-injury.
The adrenergic system has been proposed to
play an etiological role in aggression. Individuals with autism have been observed to experience hyperarousal in response to ambient
stimuli (Toichi and Kamio 2003), and it is possible that children with autism may engage in
SIB in an effort to reduce environmental stimulation (King 2000). Therefore, adrenergic antagonists are a logical option for treatment because they block sympathetic discharge and
diminish the hyperaroused state. 2-Adrenergic agonists have been suggested as candidates
for pharmacotherapy because they lower production and plasma levels of catecholamines
(Brede et al. 2003; Ihalainen and Tanila 2004).
Clonidine, for example, has been shown to reduce tics in children with Tourette syndrome
(Leckman et al. 1991) and to improve inattention, hyperactivity, and impulsivity in children
with attention-deficit/hyperactivity disorder
(ADHD) (Steingard et al. 1993; Connor et al.
1999; Hazell and Stuart 2003). Hyperactivity
and impulsivity may appear in the context of
159
autism, and as with ADHD, may also be accompanied by aggressive behavior. Therefore,
clonidine has been suggested as a treatment option for aggression and other associated symptoms of autism.
There is evidence that the endogenous opioid system may also be critical to the maintenance of aggressive behavior, particularly selfdirected aggression (Sandman et al. 1997), and
a relationship may exist between abnormalities
in the endogenous opioid system and SIB in
autism (Sandman 1988; Sandman et al. 2000).
Several studies have demonstrated elevated
plasma levels of -endorphin in some children
and adolescents with autism (Sandman 1988;
Ernst et al. 1993; Bouvard et al. 1995; Cazzullo
et al. 1999; Leboyer et al. 1999). One hypothesis posits that individuals who exhibit SIB
become endorphin dependent, and chronic elevation of -endorphin levels leads to downregulation of opioid receptors (Sandman 1988).
In these patients, SIB is maintained by the need
to release endogenous opiates to attenuate
pain. Another hypothesis suggests that chronically elevated -endorphins increase the pain
threshold, resulting in reduced responsiveness
to normal stimulation (Sandman 1988; Rothenberger 1993). Within this pain paradigm, patients initiate SIB to maintain adequate sensory
stimulation. This theoretical evidence has bolstered several trials with naltrexone in subjects
with autism. Naltrexone is a long-acting opiate
antagonist that has been observed to decrease
plasma -endorphin levels in some individuals
with autism (Bouvard et al. 1995; Cazzullo et
al. 1999).
Valproate is an anticonvulsant and mood stabilizer that is primarily used in the treatment
of seizure disorders, bipolar disorder, and migraine headaches. One proposed mechanism of
action is its effect on the function of the neurotransmitter -aminobutyric acid (GABA)
(Czapinski et al. 2005). Several observations
have triggered studies of valproate for the
treatment of aggression and self-injury in children with autism, including the presence of seizure disorders in approximately one third of
individuals with autism (Danielsson et al. 2005)
and evidence of antiaggressive properties of
valproate in animal and human models
(Molina et al. 1986; Hollander et al. 2003b; Sival
160
et al. 2004; Hollander et al. 2005b, Gobbi et al.
2006). The high incidence of epilepsy in autism
may also suggest a relationship with the phenomenon of kindling. Kindling refers to an experimental model of epilepsy where repeated
application of subthreshold electrical stimulation to the brain leads to the progressive development of spontaneous seizures. Thus, it is
possible to hypothesize a role for anticonvulsants in autism by treating subclinical epilepsy
and possibly affecting intracellular processes
involved in kindling-like models that may also
be important for related symptoms of irritability and aggression (Soderpalm 2002). Lamotrigine is also an anticonvulsant and mood stabilizer that is primarily used in the treatment
of seizure disorders and bipolar disorder. Levetiracetam is a novel anticonvulsant medication that is indicated as adjunctive therapy
in the treatment of partial-onset seizures and
primary generalized tonic-clonic seizures in
adults and children. (Physicians’ Desk Reference 2006). Along with valproate, lamotrigine
and levetiracetam have also been studied as a
potential tool to reduce aggressive behavior in
children with autism.
Secretin is an endogenous gastrointestinal
polypeptide that is produced in the cells of the
duodenum. An important hormone of the digestive system, secretin regulates pH levels in
the small intestine by reducing acid secretion
in the stomach and by triggering the release of
buffering fluids from the pancreas, liver, and
duodenum (Imamura et al. 1993). Secretin has
been suggested as a potential pharmacotherapy for autism for several reasons. First, children with autism appear to suffer from elevated rates of gastrointestinal problems
(Horvath and Perman 2002). Second, researchers have proposed that secretin may impact central nervous system function through
some as yet undetermined link between secretin receptors in the gastrointestinal system
and certain regions of the developing brain
(Horvath and Perman 2002). Finally, Horvath
et al. (Horvath et al. 1998) reported marked improvements in several social and language parameters in a series of individuals with autism
after treatment of gastrointestinal disorders
with secretin. This finding received considerable media attention, and a significant number
PARIKH ET AL.
of placebo-controlled clinical trials subsequently sought to assess the efficacy of secretin
in the treatment of autistic symptom domains.
Omega-3 long-chain-polyunsaturated fatty
acids (LC-PUFA), such as docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA),
are critical to normal brain development and
function. However, these essential nutrients,
found naturally in fish and fish oil, are often
lacking in the diets of those living in developed
countries. Recently, reports have implicated
deficiencies or imbalances in these nutrients in
the development of dyslexia (Baker 1985; MacDonell et al. 2000), ADHD (Mitchell et al. 1987;
Stevens et al. 1995; Bekaroglu et al. 1996;
Stevens et al. 1996; Burgess et al. 2000), and
autism spectrum disorders (Bell et al. 2000;
Vancassel et al. 2001; Bell et al. 2004). Conversely, supplementation of fish oils rich in
omega-3 LC-PUFA in children with autism has
reportedly led to improvements in general
health, sleeping patterns, and social behavior
(Bell et al. 2004). These observations have led
to clinical trials with these nutrients to examine their efficacy in reducing aggression in children with autism. It is important to note that
secretin and omega-3 fatty acids are more likely
to be considered novel therapies and the rationales for their use in the treatment of aggression in individuals with autism are not as
clearly defined as for most of the other medications included in this review.
To our knowledge, no recent review systematically evaluates the state of current evidence
on pharmacotherapy specifically for aggression and SIB in children with autism. Previous
reviews have examined the efficacy of medications in targeting a wide range of symptoms in
autism; most have included results from uncontrolled case reports and open-label trials,
and few have highlighted the methodological
limitations of the studies presented (Rothenberger 1993; King 2000; Hollander et al. 2003a;
McDougle et al. 2003; Aman 2004, Malone et al.
2005). We focus this review on studies in children and adolescents because of the unique
characteristics of this population and likely developmental differences in both medication response and tolerability in autism (McDougle et
al. 2003). We have chosen to select only RCTs
for review in an effort to focus on studies that
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
employ the most rigorous of scientific methodology. Although case reports and open-label
studies make meaningful contributions to the
literature, RCTs remain the gold standard for
evaluating efficacy in clinical trials. On the basis of the results of this review, we also endeavor to draw evidence-based conclusions
and to suggest directions for future research.
METHODS
Relevant studies were identified by: (1)
searching the PubMed database for Englishlanguage biomedical articles on clinical trials of
medication in the treatment of autism and
autism spectrum disorders, and (2) screening
reference lists of original studies. PubMed is a
service of the National Library of Medicine that
includes over 15 million citations from MedLine and additional life science journals that
date back to the 1950s. For inclusion in this review, identified studies were required to meet
the following a priori criteria: (1) a randomized
controlled trial of agent versus placebo or active agent; (2) a well-defined sample of subjects
that included children and adolescents with
autism or autism spectrum disorders; (3) the
use of at least one primary outcome measure
with a standardized assessment of aggression
and self-injury. Case reports, case series, and
open-label trials were excluded from this review.
RESULTS
Twenty one randomized controlled trials
were selected for inclusion in this review according to the criteria defined above. Results
are presented in Table 1. These trials examined
the efficacy and tolerability of the following
medications: risperidone, haloperidol, clomipramine, methylphenidate, tianeptine, clonidine, naltrexone, secretin, omega-3 fatty acids,
valproate, lamotrigine, and levetiracetam.
Risperidone
Three RCTs utilized a standardized outcome
measure of aggression to examine the efficacy
of risperidone, a combined dopamine and sero-
161
tonin antagonist, in children with autism. In
2002, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network
first published results from a large, multicenter trial (RUPP 2002). This first phase of the
study began as a double-blind, placebo-controlled, parallel-group trial in 101 children and
adolescents with autism over 8 weeks. Subjects
ranged in age from 5 to 17 years (mean 8.8).
Risperidone was administered at a mean dose
of 1.8 mg/day for 8 weeks. The Aberrant Behavior Checklist–Irritability (ABC-I) subscale
was the primary outcome measure of aggression and self-injury. Risperidone demonstrated
significantly greater reductions in the mean Irritability subscore as compared to placebo
(56.9% vs. 14.1%). The effect size for risperidone was 1.2 at the end of the 8-week trial.
Risperidone was also significantly more likely
to produce a positive response (69%) compared
to placebo (12%). Positive response was defined as a 25% decrease in the Irritability subscore and a rating of “much improved” or
“very much improved” on the Clinical Global
Impressions–Improvement (CGI-I) scale. Regular monitoring of side effects did not reveal
any extrapyramidal symptoms (EPS) and no
child required discontinuation due to side effects. A significantly greater mean increase
in weight occurred in the risperidone group
(2.7 2.9 kg) as compared to placebo (0.8
2.2 kg), and proportions of subjects receiving
risperidone were significantly more likely to
experience mild (49%) or moderate (24%) increases in appetite, fatigue (59%), drowsiness
(49%), drooling (27%), and dizziness (16%).
This study did employ selection criteria that
included subjects with baseline levels of aggression and SIB. The sample size was adequate, but the observation period was only 8
weeks long, and does not provide data about
sustained benefit and long-term tolerability. In
addition, given concerns about dose-related
side effects with risperidone, the minimal effective dose cannot be determined from these
results.
As part of the initial 8-week phase of the
RUPP trial, Arnold et al. (2003) asked parents
to identify one or two chief complaints of their
child’s behavior at baseline. Parents provided
full descriptions of these symptoms, including
Risperidone
Risperidone
Haloperidol
Troost et al.
2005
Shea et al.
2004
Remington
et al. 2001
Niederhofer
et al. 2003
Jaselskis
et al. 1992
Campbell
et al. 1993
Quintana
et al. 1995
Handen
et al. 2000
Risperidone
RUPP 2005b
Placebo crossover
Placebo crossover
Placebo parallel
Clonidine
Naltrexone
Placebo crossover
Methylphenidate
Tianeptine
Placebo crossover
Pacebo crossover
Placebo
Placebo
discontinuation
Placebo
discontinuation
Placebo
parallel
Methylphenidate
Clomipramine
Risperidone
Design
OF
MEDICATIONS
FOR
12 male children
and adolescents
8 male children
and adolescents
41 children
13 children
10 children
36 children and
adults
(24 18 yrs)
80 children
24 children and
adolescents
32 children and
adolescents
101 children and
adolescents
Sample
RANDOMIZED CONTROLLED TRIALS
Medication
RUPP 2002
Authors, date
TABLE 1.
AND
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Selected/stratified
by aggression?
AGGRESSION
SIB
CHILDREN
ARS
ABC-I
ABC-I
ABC-I
IOWA
ABC-I
ABC-I
ABC-I
ABC-I,
N-CBRF
ABC-I
CGI-SOSC
ABC-I
CGI-I
ABC-I
Measure
IN
Outcome
ADOLESCENTS
Negative
Positive
Positive
Positive
Positive
Negative
Negative
Positive
Positive
Positive
Positive
AND
AUTISM
Side effects
Drowsiness; decreased
activity; hypotension
Vomiting (n 3); excessive
sedation (n 2); decreased
appetite (n 2)
Somnolence (n 2);
hyperkinesias (n 1);
weight gain (n 1);
aggression (n 1);
extrapyramidal disorder
(n 1)
Fatigue/lethargy (n 5);
dystonia (n 1);
depression (n 1)
Fatigue/lethargy (n 4);
tremors (n 2);
tachycardia (n 1);
insomnia (n 1);
diaphoresis (n 1);
nausea/vomiting (n 1);
decreased appetite (n 1)
No differences between
groups
Social withdrawal (n 2);
dullness (n 1); sadness
(n 1); irritability (n 1);
skin picking (n 1)
Drowsiness
Not reported
Weight gain (mean 2.7 kg);
fatigue (59%); increased
appetite (49%); drowsiness
(49%); drooling (27%);
dizziness (16%)
Not reported
WITH
Placebo parallel
Placebo crossover
Secretin
Omega-3
fatty acids
Placebo crossover
Secretin
Placebo crossover
Placebo crossover
Secretin
Secretin
Placebo parallel
Levetiracetam
Placebo crossover
Placebo parallel
Lamotrigine
Secretin
Placebo parallel
Placebo crossover
Naltrexone
Valproate
Placebo crossover
single dose
Naltrexone
13 male children
and adolescents
42 children
and adolescents
85 children
19 children
8 children
56 children
20 children
30 children
and adolescents
35 children
20 children
20 children
Yes
No
No
No
No
No
No
No
Yes
No
No
ABC-I
ABC-I
ABC-I
ABC-I
ABC-I
ABC-I
ABC-I
ABC-I
OAS
ABC-I
ABC-I
ABC-I
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive per
teacher
Negative per
parent
Negative
Positive
No differences between
groups
Not reported
Severe tantrums, screaming,
hyperactivity, and
aggression (n 1)
Not reported
Increased appetite (n 9);
skin rash (n 7)
No differences between
groups
No differences between
groups
No differences between
groups
Not reported
No differences between
groups
No differences between
groups
Abbreviations: ABC-I Aberrant Behavior Checklist–Irritability subscale; IOWA IOWA Conners’ Teacher Rating Scale; CGI-I Clinical Global Impressions–
Improvement Scale; CGI-SOSC Clinical Global Impressions–Scale of Symptom Change; N-CBRF Nisonger–Child Behavior Rating Form; ARS Aggression Rating
Scale; OAS Overt Aggression Scale; SIB self-injurious behavior.
Molloy
et al. 2002
Unis
et al. 2002
Amminger
et al. 2007
Hellings
et al. 2005b
Belsito
et al. 2001
Wasserman
et al. 2006
Owley
et al. 2001
Carey
et al. 2002
Kern
et al. 2002
WilemsenSwinkels
et al. 1995
WilemsenSwinkels
et al. 1996
164
frequency, duration, intensity, and ability to interfere with daily life. At each subsequent visit,
parents were asked to describe how the identified symptoms had changed since beginning
the trial and these descriptions were then
recorded and rated by independent, blinded
judges on a 9-point scale. Among the symptoms identified by parents in this study, selfinjury (effect size 2.11) and aggression (effect
size 1.66) showed the greatest improvement
in subjects who received risperidone.
At the end of the initial 8-week RUPP trial,
participants who showed a positive response
to risperidone were enrolled in an extension
study (RUPP 2005b). A 4-month open-label
phase was followed by an 8-week doubleblind, placebo-controlled, parallel-group discontinuation trial. In the placebo arm of this
discontinuation trial, risperidone was gradually replaced by placebo over 4 weeks, followed
by a 4-week period in which subjects received
placebo alone. In the risperidone arm of this
discontinuation study, risperidone dosage was
maintained. Behavioral relapse was defined as
a 25% increase in the ABC-I subscale and a rating of “much worse” or “very much worse” for
at least two consecutive weeks on the
CGI–Scale of Symptom Change. Thirty two
subjects completed the discontinuation trial,
and interim analysis revealed a 62.5% rate of
behavioral relapse for subjects in the placebo
arm as compared to 12.5% for subjects who
continued to receive risperidone. The discontinuation trial was then terminated by the National Institute of Mental Health (NIMH) Data
and Safety Monitoring Board on the basis of
these interim results. Although the study did
select subjects based on levels of aggression, interpretation of its results is limited by the fact
that only those participants who responded to
risperidone were included in this extension
study. Furthermore, the validity of discontinuation trials may be called into question given
the risk of discontinuation symptoms, despite
the taper, and the potential for blinding to have
been compromised.
Troost et al. (2005) conducted the second
RCT that used a standardized measure of aggression to examine the efficacy of risperidone
in children and adolescents with pervasive developmental disorders (PDD). After an initial
PARIKH ET AL.
24-week open-label phase, 24 responders were
identified for entry into an 8-week doubleblind, placebo-controlled, parallel-group discontinuation phase. In the placebo group,
risperidone was gradually replaced by placebo
over a period of 3 weeks, followed by placebo
alone for 5 weeks. In the risperidone group,
dosages were maintained for 8 weeks. The
mean age of the subjects was 9 years. For subjects who remained on risperidone, the mean
dose was 1.81 mg/day. Relapse was defined as
a 25% increase in the ABC-I subscale and a rating of “much worse” or “very much worse” for
at least 2 consecutive weeks on the CGI–Scale
of Symptom Change in reference to behavior.
At study end point, significantly more subjects
relapsed in the placebo group (67%) as compared to those who continued to receive
risperidone (25%). Over the duration of the discontinuation phase, subjects who received
placebo also showed a significantly greater increase in ABC-I subscore (60%) as compared to
risperidone (14%).
This study did select subjects with aggression and SIB, but other potential confounders
limited interpretation of the results. As with the
RUPP discontinuation study, only responders
to the open-label trial were selected for inclusion in the placebo-controlled phase; the nature
of the design may also increase the likelihood
of relapse, increase the risk of other discontinuation side effects, and compromise blinding.
In addition, these results may have been influenced by type I error because of small samples
in each treatment arm (n 12). Other limitations include the overrepresentation of relatively high-functioning male children (90%)
and subsequent difficulty generalizing these
results to lower functioning, female, or adolescent populations.
The third RCT of risperidone was conducted
in 80 children and adolescents with pervasive
developmental disorders by Shea et al. (2004)
using a double-blind, placebo-controlled, parallel-group design over 8 weeks. Subjects
ranged in age from 5 to 12 years old (mean
7.5) and risperidone was administered at a
mean dose of 1.17 mg/day (0.04 mg/kg per
day). The ABC-I subscale was the primary outcome measure of aggression and the Nisonger
Child Behavior Rating Form (N-CBRF), which
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
includes a conduct problem subscale, was also
used. Mean ABC-I scores decreased for both
groups at each weekly visit, although the mean
decrease in subjects receiving risperidone was
significantly greater as compared to placebo.
Over the duration of the study period, subjects
receiving risperidone had approximately twice
the mean decrease in ABC-I subscore as compared to placebo. Significantly lower scores on
the N-CBRF conduct problem subscale were
also found in the risperidone group. There
were no significant differences in the incidence
of EPS between the two groups according to
the Extrapyramidal Symptom Rating Scale.
Subjects who received risperidone gained significantly more weight on average (2.7 kg) than
those on placebo (1.0 kg). The most common
adverse events experienced by subjects in the
risperidone group were somnolence (72.5%),
upper respiratory tract infection (37.5%), rhinitis (27.5%), and increased appetite (22.5%).
Among those who reported somnolence in the
risperidone group, resolution was achieved in
the majority of cases (86.2%) through dose reduction or no action. Among the 40 subjects in
the risperidone group, 5 experienced adverse
events that were considered severe: hyperkinesia and somnolence (n 1); severe weight
gain (n 1); somnolence (n 1); aggressive reaction with impaired concentration (n 1);
and extrapyramidal disorder as a result of accidental overdose (n 1). Aside from weight
gain, the authors did not report whether the
rates of any of these adverse events differed between the risperidone and placebo groups.
Limitations of this study include its short duration and the fact that subjects were not selected or stratified according to baseline levels
of aggression.
Haloperidol
One RCT has examined the efficacy of
haloperidol, a dopaminergic antagonist, with a
standardized outcome measure of aggression
and self-injurious behavior in children with
autism. In their study, Remington et al. (2001)
compared clomipramine, haloperidol, and
placebo in 36 subjects over 7 weeks using a
double-blind, placebo-controlled, crossover design with 1-week washout periods separating
165
the three treatment arms. Subjects ranged in
age from 10 to 36 years (mean 16.3) and 24
subjects were less than 18 years of age. All met
the Diagnostic and Statistical Manual for Mental
Disorders (DSM-IV) (American Psychiatric Association 1994) criteria for autism. Haloperidol
was administered in a daily dose of 1.3
mg/day. The ABC-I subscale was the primary
outcome measure of aggression and self-injurious behavior. No significant difference was
found in aggression and self-injury with
haloperidol as compared to placebo controls. A
global side effects scale and the Extrapyramidal Symptom Rating Scale were used to monitor medication tolerability. Ten of 33 subjects
prematurely discontinued the haloperidol
treatment arm due to “behavioral problems”
(n 3), fatigue/lethargy (n 5), depression
(n 1), and dystonia (n 1). Eleven of 32 subjects prematurely discontinued the placebo arm
due to “behavioral problems” (n 10) and
nosebleeds (n 1).
Subjects in this study were not selected for
aggression, and these results may also be called
into question by the presence of possible carryover effects between treatment groups and
placebo. In addition, the daily dose of haloperidol (1.3 mg) may not have been sufficient to
produce meaningful therapeutic benefit.
Methylphenidate
Two RCTs have utilized a primary outcome
measure of aggression to examine the efficacy
and tolerability of methylphenidate, a dopaminergic agonist, in children and adolescents
with autism. Quintana et al. (1995) conducted
the first study in 10 subjects with autism over
4 weeks using a double-blind, placebo-controlled, crossover design. Subjects ranged in
age from 7 to 11 years (mean 8.5). Methylphenidate was administered in divided doses
equaling 20 and 40 mg/day. The ABC-I subscale was the primary outcome measure of
aggression and SIB and was completed independently by two psychiatrists during 3-hour
observation sessions that included a simulated
structured classroom situation with classroom
tasks and free play. From a mean baseline subscore of 11.8 11.2, methylphenidate produced significant improvements in ABC-I
166
mean endpoint subscore (4.0 3.8) as compared to placebo mean endpoint score (7.2
6.3) (p 0.01). Tolerability was assessed using
a side effects checklist and no significant differences were found in the rates of side effects
between methylphenidate and placebo.
Handen et al. (2000) conducted the second
RCT of methylphenidate in 13 children diagnosed with autism or PDD not otherwise specified (NOS) over 7 days using a double-blind,
placebo-controlled, crossover design. Subjects
ranged in age from 5.6 to 11.2 years (mean
7.4). Methylphenidate was administered in low
(0.3 mg/kg per dose) and high (0.6 mg/kg per
dose) doses two to three times daily. Primary
outcome measures of aggression were the
ABC-I subscale and the aggression subscale of
the IOWA Conners’ Teacher Rating Scale. As
compared to placebo, subjects who received
methylphenidate showed significant improvement on both outcome measures. A side effects
checklist was used to assess tolerability. A relatively high number of subjects (9 of 12) reportedly experienced some “side-effects” while
on placebo. A total of 5 children experienced
severe side effects while receiving methylphenidate, including social withdrawal, dullness,
sadness, irritability, and skin picking. These
side effects caused three subjects to be discontinued from the study.
Both RCTs of methylphenidate studies produced significant results, but several shortcomings are notable. Sample sizes were small
and the study duration was relatively short.
Furthermore, subjects were not stratified according to levels of aggression and a wide
range of behaviors was noted among subjects
at baseline.
Clomipramine
Two RCTs have used standardized outcome
measures of aggression in examining the use of
serotonergic medications as a treatment for
children and adolescents with autism. The first
was the aforementioned study by Remington
et al. (2001). Clomipramine doses began at 25
mg/day and were titrated to an average final
dose of 128.4 mg/day. The Irritability subscale
of the ABC was the primary outcome measure
of aggressive and self-injurious behavior. The
PARIKH ET AL.
results of this study did not demonstrate a significant difference between clomipramine and
placebo scores on the ABC-I subscale. Twenty
subjects discontinued clomipramine prior to
week 7, and 12 cited side effects as the reason:
fatigue/lethargy (n 4), tremors (n 2),
tachycardia (n 1), insomnia (n 1), diaphoresis (n 1), nausea/vomiting (n 1), and decreased appetite (n 1). The remaining 8 subjects discontinued specifically because of
“behavioral problems,” reportedly due to lack
of drug efficacy.
The results of this study must be interpreted
with caution, however, because significantly
fewer subjects in the clomipramine group were
able to complete the trial. In addition, potential
carryover effects likely exist when these medications are used in sequence with only 1-week
washout periods and may have artificially inflated the placebo effect. Subjects were also not
stratified according to baseline levels of aggression and this may impact the validity of
post-intervention assessments.
Tianeptine
The second RCT of a serotonergic medication
examined tianeptine, an agent that reportedly
increases serotonin reuptake (Sweetman 2004).
Tianeptine was studied by Niederhofer et al.
(2003) in 12 male children with autism over 12
weeks using a double-blind, placebo-controlled, crossover design. Subjects ranged in
age from 4.2 to 14.9 years (mean 7.3). Tianeptine was administered in a dose of 37.5 mg
daily. The ABC was completed by parents and
teachers and the Irritability subscale was used
as the primary outcome measure of aggressive
and self-injurious behavior. At study endpoint,
results indicated a significant difference between tianeptine and placebo on the ABC-I
subscale according to parent and teacher ratings, although this difference was not significant at the study midpoint of 6 weeks. Medication tolerability was monitored using a
symptom checklist of potential side effects.
Drowsiness and decreased activity were significantly increased in patients receiving
tianeptine at both 6 and 12 weeks.
Several methodological limitations of this
study also need to be considered. Only 12 sub-
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
jects were included and the sample was not
stratified using baseline assessments of aggression. It is also important to note that clinician ratings did not demonstrate a significant
difference between tianeptine and placebo, although the trial duration may not have been
sufficient to assess the therapeutic benefit fully.
Due to increased rates of drowsiness among
subjects who received tianeptine, parents and
teachers may have effectively become unblinded. Finally, because this study used a
crossover design with only a 1-week washout
period, carry-over effects are also possible.
Clonidine
One RCT has used a standardized outcome
measure to examine the ability of an adrenergic
agent to reduce aggression and SIB in children
and adolescents with autism. Jaselskis et al.
(1992) conducted a study of clonidine in 8 male
subjects with autism for 6 weeks using a doubleblind, placebo-controlled, crossover design. Subjects ranged in age from 5 to 13.4 years (mean
8.1). Clonidine was administered in daily doses
of 0.15 to 0.20 mg/day. Teacher rating of the
ABC-I subscale was the primary outcome measure of aggression and self-injury. The results of
this study demonstrated that children who received clonidine had significantly lower ABC-I
subscale scores as compared to placebo. Clonidine was significantly more likely to cause
drowsiness and decreased activity, and the onset of hypotension necessitated dose reduction in
3 children during the study.
Clinician ratings were not sensitive to effects
for clonidine, however, and several limitations
may have biased these results. The sample size
was small and subjects were not selected for
aggressive behavior. Six weeks may also not
have been a sufficient duration to detect full
therapeutic benefit, and crossover effects may
have played a role despite the 1-week washout
period in between arms. Finally, the greater
likelihood of drowsiness among subjects who
received clonidine may have compromised the
blinding of parents and teachers.
Naltrexone
Three RCTs have used a standardized primary outcome measure of aggression to exam-
167
ine the efficacy of naltrexone in children with
autism. The first was conducted by Campbell
et al. (1993) in 41 children diagnosed with autistic disorder using a double-blind, placebo-controlled, parallel-group design over 4 weeks.
Subjects ranged in age from 2.9 to 7.8 years
(mean 4.9). Naltrexone was administered in
a daily dose of 0.5 mg/kg for 1 week, and then
increased to 1.0 mg/kg for 2 weeks. After 3
weeks, all subjects entered a 1-week post-treatment placebo phase. The Aggression Rating
Scale was the primary outcome measure of aggression and self-injury. There was no significant improvement in the severity of SIB or aggression in subjects receiving naltrexone as
compared to placebo. Overall, adverse effects
were reportedly similar in nature and frequency between the two groups; excessive sedation (n 3), decreased appetite (n 2), and
vomiting (n 3) were only observed in children who received naltrexone. This study did
not select or stratify subjects according to levels of aggression and it is possible that the dose
of naltrexone was not sufficient to achieve therapeutic benefit.
Willemsen-Swinkels et al. (1995) conducted
the second RCT of naltrexone in 20 children
with autism using a double-blind, placebo-controlled, single-dose, crossover design. Subjects
ranged in age from 3 to 7 years (mean 5.5).
Naltrexone was administered in a single dose
of 40 mg (1.48 mg/kg to 2.35 mg/kg; mean
1.96 mg/kg). The ABC-I subscale was the primary outcome measure of aggression and selfinjury. Naltrexone produced a significantly
greater reduction in the ABC-I subscore as
compared to placebo. Plasma -endorphin levels and liver function were monitored and remained within normal limits after administration of naltrexone.
In an extension of this study, WillemsenSwinkels et al. (1996) examined the effects of
longer-term administration of naltrexone in 20
children with autism using a double-blind,
placebo-controlled, crossover design over 8
weeks (4 weeks in each treatment arm). Naltrexone was administered in doses that ranged
from 0.74 mg/kg per day to 1.18 mg/kg per
day (mean 0.98 mg/kg per day). Parents and
teachers completed the ABC-I subscale as the
primary outcome measure of aggressive and
168
self-injurious behavior. The results of this
study did not demonstrate significant differences between placebo and naltrexone in ABCI subscores as rated by the parents. However,
teacher ratings of the ABC-I subscores did
show significant improvement with naltrexone. No serious adverse effects were reported.
These results are confounded by the relative
absence of aggression at baseline; only 2 of the
20 subjects reportedly demonstrated “mild
SIB.” Despite producing a significant effect in
the first of these two studies, the limitations of
a one-time dose of naltrexone are self-evident.
Interestingly, the 8-week follow-up study did
not produce significant results, except on
teacher ratings. The inconsistency between parent and teacher ratings calls these results into
question, especially given the absence of
blinded clinician ratings.
Valproate
One RCT has utilized a standardized assessment of aggression and self-injury to examine
the efficacy of valproate in children and adolescents with autism, Asperger syndrome, and
PDD-NOS. Hellings et al. (2005b) studied a
sample of 30 subjects using a double-blind,
placebo-controlled, parallel-group design over
8 weeks. Subjects ranged in age from 6 to 20
years. Subjects were required to exhibit significant aggression to self, others, or property at
least three times per week for inclusion in the
trial. Valproate was administered in doses of
20 mg/kg per day. The ABC-I subscale and the
Overt Aggression Scale (OAS) were used to assess aggression and self-injury. No significant
differences emerged between treatment groups
on either the ABC-I subscale or the OAS. Side
effects were measured by a checklist derived
from the Physicians’ Desk Reference. Subjects in
the valproate group were significantly more
likely to report increased appetite (n 9).
Other side effects included weight gain (n 7),
skin rash (n 6), nausea (n 4), vomiting (n
4), diarrhea (n 4), fever (n 4), drowsiness
(n 3), lethargy (n 3), chills (n 3), and constipation (n 2), but these did not differ significantly between valproate and placebo.
This study did select subjects for aggression
and SIB. However, the authors reported high
PARIKH ET AL.
intrasubject variability in severity and frequency of aggression during the 8-week period, which likely weakens study power. Results must also be interpreted with caution
because of small group sizes and a high placebo
response rate. In addition, the duration of the
study may not have been sufficient. After a 1week placebo run-in and valproate titration,
adequate doses were only maintained for approximately 4 weeks. Finally, mean valproate
blood level was 77.7 mcg/dL at week 8, and
higher doses/blood levels may be required to
achieve meaningful benefit and demonstrate
statistical separation from placebo.
Lamotrigine
Belsito et al. (2001) conducted the only RCT
of lamotrigine to use a standardized assessment of aggression and self-injury in 35 youths
with autism. The authors used a double-blind,
placebo-controlled, parallel-group design over
18 weeks. Subjects ranged in age from 3 to 11
years (mean 5.8). Lamotrigine was titrated to
a mean dose of 5 mg/kg per day over 8 weeks,
and was then maintained for an additional 4
weeks. Following the titration and maintenance phases, subjects were tapered over 2
weeks and then entered a final 4-week drugfree phase. The ABC-I subscale was the primary outcome measure of aggression and selfinjury. No significant differences were found
between ABC-I subscores in children receiving
lamotrigine and those on placebo. All subjects
were monitored for side effects, and rates did
not differ significantly between groups. This
study did not select for subjects with aggression at baseline and groups were not stratified
according to levels of aggression. Small group
sizes may also have weakened the power to detect significant differences between lamotrigine
and placebo. Furthermore, subjects were only
maintained on a therapeutic dose of lamotrigine for 4 weeks and this may not have been of
sufficient duration to assess benefit.
Levetiracetam
One RCT has utilized a standardized outcome measure of aggression to examine the efficacy of levetiracetam in children with autism.
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
Wasserman et al. (2006) studied 20 children
with autism spectrum disorders using a double-blind, placebo-controlled, parallel-group
design over 10 weeks. Participants ranged in
age from 5 to 17 years (mean 8.72). Levetiracetam was titrated to a mean dose of 862.50
mg/day. Parent and teacher ratings of the
ABC-I subscale were used to monitor aggressive behavior in the study subjects. No significant differences were found between parent
ratings of the ABC-I subscale in subjects receiving levetiracetam and those on placebo.
Teacher ratings, on the other hand, showed a
significant time by treatment interaction, indicating that the levetiracetam group increased
in irritability, whereas the placebo group became less irritable. Tolerability was monitored
via regular reports of side effects, although statistical analyses of the side effect reports are not
presented Participants receiving placebo experienced agitation (n 1), aggression (n 1),
enuresis (n 1), and insomnia (n 1). In the
levetiracetam group, participants experienced
agitation (n 1), aggression (n 2), hyperactivity (n 1), impulsivity (n 1), loss of appetite (n 1), self-injurious behavior (n 1),
weight gain (n 1), and weight loss (n 1).
Two subjects in the placebo group withdrew
from the study, 1 due to increased hyperactivity, and 1 due to seizure. One subject in the levetiracetam group dropped out from the study
due to lack of efficacy. Interpretation of the
study is limited by the small sample size and
by the inconsistency between parent and
teacher ratings of the ABC-I subscale. Also,
study participants were neither selected nor
stratified according to baseline levels of aggression.
Secretin
Five RCTs have used a standardized outcome measure of aggression and self-injury to
examine the use of secretin in children and adolescents with autism or PDD-NOS. All five
used a double-blind, placebo-controlled, single-dose, crossover design over 3–6 weeks
(Owley et al. 2001; Carey et al. 2002; Kern et al.
2002; Molloy et al. 2002; Unis et al. 2002). Sample sizes ranged from 8 (Carey et al. 2002) to 85
(Unis et al. 2002) children and adolescents aged
169
3 to 15 years. Secretin was always administered
in a one-time infusion of 2 CU/kg or its equivalent and assessments were then collected over
the duration of the studies using the ABC-I subscale as the primary outcome measure of aggression and self-injury. None of the studies
found significant differences in ABC-I subscores between subjects who received secretin
and those who received saline infusion. Post
hoc analysis of one study (Kern et al. 2002)
found that children with a history of chronic
diarrhea who received secretin showed significant improvement in the ABC-I subscore as
compared to baseline, and these improvements
were not found in children who received
placebo. Adverse effects were not systematically assessed, although one study (Owley et
al. 2001) reported abdominal rash (n 1), nonfebrile seizures (n 1), and vomiting (n 2) in
children receiving secretin. In another study
(Kern et al. 2002), one subject was noted to exhibit dramatic increases in tantrums, screaming, hyperactivity, and aggression following secretin infusion. Although replication across
studies makes the results appear convincing,
none of these studies selected subjects according to baseline levels of aggression or later
stratified the samples to assess differential effects. In addition, all used a single dose of secretin that may have been insufficient and the
effect of multiple doses has not been tested in
a placebo-controlled design.
Omega-3 fatty acids
One RCT examined the efficacy of omega-3
fatty acids in children with autistic disorder using a standardized assessment of aggression
and self-injury. Amminger et al. (2007) studied
13 boys using a double-blind, placebo-controlled, parallel-group design over 6 weeks. Selection criteria for the study included an age of
5–17 years, a mental age of at least 18 months,
and a score of greater than 17 on the ABC-I subscale. The mean age of subjects receiving
omega-3 fatty acids was 10.5 years. The mean
age in the placebo group was 12.1 years. Participants in the experimental group received 1.5
grams/day of omega-3 fatty acids (0.84 grams/
day of eicosapentaenoic acid, and 0.7 grams/
day of docosahexaenoic acid). The ABC-I sub-
170
PARIKH ET AL.
scale was used to assess aggressive and selfinjurious behavior. No statistically significant
differences were found between treatment
groups in scores or improvements on the ABCI subscale. Although no standardized assessments of adverse effects appear to have been
conducted, fever was reported in the experimental group and headache and insomnia
were reported in the placebo group.
This study did select subjects for aggression
by requiring a minimum score on the ABC-I
subscale. Nevertheless, interpretation of the
study’s results is limited by its small group
sizes and short study duration. If imbalances
of these nutrients play a critical role in brain
function and development, it is possible that
therapeutic benefit may not occur within 6
weeks.
DISCUSSION
Among the 21 randomized controlled studies to employ a standardized primary outcome
measure of aggression or self-injury to examine the efficacy of medication in children with
autism, five medications produced significant
results as compared to placebo. These medications include risperidone, methylphenidate,
tianeptine, clonidine, and naltrexone.
Risperidone is the medication with the most
evidence to support its use for aggression and
SIB in children and adolescents with autism.
Results are also consistent across several studies with similar designs, particularly those conducted by the RUPP (2005b) and Troost et al.
(2005). Furthermore, this medication recently
received an indication by the FDA for aggression toward others and deliberate self-injurious
behavior in autism (FDA 2006). Although it has
been suggested that symptom improvement
may only occur as a result of sedation, post hoc
analysis in one study (Shea et al. 2004) found
comparable changes in ABC-I subscores between risperidone-treated subjects who experienced somnolence and those who did not. In
contrast to the first-generation antipsychotic
(FGA) haloperidol, this second-generation antipsychotic (SGA) appears to be both effective
and well-tolerated. According to studies in
adult populations with schizophrenia, risperi-
done also has a lower risk of EPS and tardive
dyskinesia (Dossenbach et al. 2004; Schooler et
al. 2005). This difference is believed to arise
from blockade of serotonin-type 2 receptors
(Findling et al. 1997; Masi et al. 2003). Combined serotonergic activity of risperidone may
also contribute to its effectiveness in reducing
aggressive behavior in children with autism.
Yet, all SGAs combine dopamine and serotonin
antagonism in their mechanism of action, and
only risperidone has been studied under
placebo-controlled conditions for the treatment
of aggression in autism. Placebo-controlled trials of other SGAs are needed to determine if
there are effective alternatives to risperidone
among this class of medications. The risks of
risperidone include significant weight gain and
increased vulnerability to diabetes and cardiovascular disease later in life. The metabolic syndrome, characterized by obesity, dyslipidemia,
and abnormalities of glucose homeostasis, has
also been described in adult populations
treated with SGAs (Mackin et al. 2005). Therefore, nutritional counseling and a physical activity regimen should be included for all children treated with risperidone.
In addition to weight gain, hyperprolactinemia has arisen as a safety concern with the use
of risperidone. The release of the hormone prolactin is mediated by dopaminergic inhibition,
and dopamine antagonists may consequently
increase prolactin secretion. Anderson et al.
(2007) conducted an analysis of the RUPP 8week randomized controlled trial of risperidone in 101 children with autism discussed
above. They found significant elevations in
prolactin levels in subjects treated with risperidone as compared to placebo controls. An additional, open-label study of children with
autism treated with risperidone found two-fold
increases in serum prolactin levels over a period of at least 26 weeks (Hellings et al. 2005c).
Other studies have reported similar prolactin
elevations in children, adolescents, and adults
treated with risperidone (Malone et al. 2002;
Patel et al. 2005). Hyperprolactinemia may result in galactorrhea, dysmenorrhea, sexual dysfunction, and osteoporosis in females, and can
lead to gynecomastia, erectile difficulties, and
impaired spermatogenesis in males (Haddad
and Wieck 2004). However, there is evidence
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
that prolactin release may gradually diminish
to near-normal levels over long-term risperidone use and that hyperprolactinemia is not associated with any interference in growth or sexual maturation (Malone et al. 2002; Patel et al.
2005; Anderson et al. 2007). In the absence of
clinical signs, the utility of monitoring prolactin
levels in patients treated with risperidone remains an area of debate. Additional long-term
studies are needed to understand the impact of
risperidone treatment in children and adolescents with autism. Another related issue that
warrants further study is the differential effect
of dosing on the risk of metabolic and endocrine changes.
Two RCTs found methylphenidate to improve symptoms of aggression and SIB effectively in children and adolescents with autism.
The predominant symptoms that stimulant
medications target are hyperactivity, attention
deficit, and impulsivity. Past studies have
found stimulants, such as methylphenidate, to
be both efficacious and tolerable in treating
populations with autism (Hoshino et al. 1977;
Birmaher et al. 1988; Strayhorn et al. 1988). A
double-blind, placebo-controlled study conducted by the RUPP, for example, found significant improvements in ABC-hyperactivity
subscores in 72 children with autism spectrum
disorders who were treated with methylphenidate as compared to placebo. It is important to
note that the ABC-I subscale was a secondary
outcome measure of this study, but that no significant improvements in Irritability subscores
were found between those receiving methylphenidate and those on placebo (RUPP 2005a).
The two RCTs included in this review were the
only to use an assessment of aggression and SIB
as primary outcome measures and both studies demonstrated significant improvements
overall. There were reports of worsening irritability and self-injury in some individuals, although the specific number of subjects who experienced such paradoxical effects was not
reported. Previous studies have also documented paradoxical reactions to stimulants,
particularly in developmentally disabled populations (Handen et al. 1991; RUPP 2005a),
highlighting the need to exercise caution in prescribing these medications in children and adolescents with autism. Nevertheless, stimulant
171
medications such as methylphenidate are generally well tolerated and effective in children
and adolescents with ADHD (Greenhill et
al. 2001). In general, and specifically with
methylphenidate, clinical trials to assess the effects of treatment on aggressive behavior in
children with autism should either select subjects with aggression or stratify the sample according to baseline levels. Analyses may then
reveal a subset of children with autism that reliably respond to methylphenidate treatment.
The effect of stimulants in individuals with
autism spectrum disorders is likely less reliable
than in typically developing children with
ADHD, but additional placebo-controlled
studies are nevertheless warranted.
Tianeptine is reported to be a serotonin reuptake enhancer and an anxiolytic medication
that is approved and marketed in a number of
countries in Europe, Asia, and Latin America
(Sweetman 2004). While potentially effective,
its practical application for children with
autism in the United States is limited at this
time. The endorsement of this medication for
the treatment of aggression in autism is also
challenged by the presence of only one placebocontrolled study with several methodological
limitations. In addition, the tolerability of
tianeptine requires further study.
Despite theoretical support for adrenergic
dysregulation as an etiological factor in aggression, only one RCT has examined this system as a pharmacological target in children
with autism. The results demonstrate that
clonidine improves symptoms of aggression in
autism. However, clonidine did produce a significant increase in drowsiness, which therefore introduces the possibility that effects on
aggression may have occurred secondary to sedation. In addition, the risk of hypotension
warrants close monitoring. The results of this
trial are compelling, but additional placebocontrolled studies are needed to replicate these
findings and clarify issues of tolerability.
With regard to the efficacy of naltrexone in
treating aggression and self-injury in children
with autism, results are equivocal. In one of the
three RCTs, no significant improvement was
found in the severity of SIB or aggression in
subjects receiving naltrexone (Campbell et al.
1993). The second study found that a single
172
dose of naltrexone produced significant effects,
but only 2 of the 20 children enrolled in the
study manifested symptoms of self-injury at
baseline (Willemsen-Swinkels et al. 1995). In a
follow-up to this study, subjects maintained
improvement on naltrexone over 8 weeks, but
only according to teacher ratings and not parent ratings (Willemsen-Swinkels et al. 1996).
Much effort has been dedicated to identifying
a subset of children with autism that respond
to naltrexone based on evidence that individuals with autism have elevations in plasma
-endorphin concentrations (Sandman 1988;
Ernst et al. 1993; Bouvard et al. 1995; Cazzullo
et al. 1999; Leboyer et al. 1999). Some have suggested an association between higher levels of
endogenous opiates and elevated rates of selfinjury (Gillberg 1995) or an ability to predict
SIB based on plasma concentration levels
(Sandman 1988), yet others found no such
relationship (Ernst et al. 1993; WillemsenSwinkels et al. 1995). Research on the effect of
naltrexone on -endorphin levels in individuals with autism remains similarly inconclusive.
Studies have reported that naltrexone produces
no change (Willemsen-Swinkels et al. 1995),
significant increases (Zingarelli et al. 1992), and
significant decreases (Bouvard et al. 1995; Cazzullo et al. 1999) in plasma levels of -endorphin in individuals with autism. Few studies
have systematically assessed side effects of naltrexone in children with autism, although most
describe it as safe and well tolerated. Side effects are reportedly mild, and rates are comparable to placebo (Elchaar et al. 2006). The endogenous opioid system was once considered
a promising line of study; however, recent efforts to pursue this system as a medication target in autism have waned. Current results are
inconsistent and additional studies are likely
required before naltrexone may be considered
a reliable option for treating aggression and SIB
in autism.
Placebo-controlled studies have also assessed the efficacy of clomipramine and
haloperidol, secretin, omega-3 fatty acids, valproate, lamotrigine, and levetiracetam, although results to date do not show significant
benefit in treating aggression. Secretin, in particular, has been examined in five RCTs, none
of which demonstrated significant results.
PARIKH ET AL.
Clomipramine also failed to demonstrate significant improvement in aggression and SIB,
but this trial represents the only attempt to
study a serotonin reuptake inhibitor for aggression in autism. This is despite evidence
from several open-label and placebo-controlled
studies of selective serotonin reuptake inhibitors in treating associated symptoms of autism,
such as repetitive behavior (Fatemi et al. 1998;
Couturier and Nicolson 2002; Namerow et al.
2003; Owley et al. 2005). The serotonergic system remains a compelling candidate for targeted treatment aimed at reducing aggression
and SIB in autism.
Omega-3 fatty acids, valproate, lamotrigine,
and levetiracetam studies do not have convincing data that demonstrate improvement in
aggression and SIB among children and adolescents with autism according to the results of
this review. However, only one RCT was done
to examine the efficacy of each. In addition, an
open-label extension trial at the end of the valproate RCT (Hellings et al. 2005b) found that
attempts to taper the medication resulted in a
worsening of irritability and aggression. Although these results must be interpreted with
caution, combined with results from an openlabel study (Hollander et al. 2001), evidence remains to suggest that a subgroup of individuals with autism may experience improvement
in aggression with valproate. Additional
placebo-controlled trials are necessary and
known to be in progress or under review. It is
also important to note that there is a higher risk
of life threatening rash with lamotrigine in pediatric patients than in adults (Physicians’ Desk
Reference 2006).
The treatment of autism requires targeted approaches to different symptom domains. This
review selected aggression and SIB because of
the frequent need for pharmacological intervention and the relative paucity of effective
treatment options. Whereas this review is both
comprehensive and focused, it is nonetheless
important to delineate some weaknesses. First,
few of the studies we reviewed selected sample populations on the basis of aggression. Future studies would be strengthened by utilizing such selection criteria or by stratifying
subjects according to baseline levels of aggression.
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
Second, in an effort to assess specifically the
impact of medication on aggression and SIB,
we focused only on studies that employed at
least one primary outcome measure of aggression. Yet, few studies specifically examined aggression using such measures, and in those that
did, the ABC-I subscale was the predominant
instrument. This subscale includes questions to
assess aggression and self-injury, but may not
be as specific as the OAS, for example, which
includes direct measures of aggression directed
at others, aggression toward property, and SIB
(Hellings et al. 2005a). Nevertheless, the ABCI subscale has been validated as a tool to measure aggression in children (Aman et al. 1985)
and did meet our a priori criteria.
Third, this review chose to focus only on
studies that included children and adolescents
in their sample. This criterion was used because
aggression and SIB occur commonly in children with autism (RUPP 2002) and because less
is known about the nature and impact of psychotropic medications in this population. However, studies in adult populations were excluded, and perhaps their inclusion would
have altered our results. A marked difference
in the efficacy and tolerability of medications
in children and adolescents as compared to
adults with autism has been documented in
studies of fluvoxamine (McDougle et al. 1996b;
Martin et al. 2003), for example, and this highlights the importance of considering developmental factors when prescribing these medications.
Finally, our criteria defined only randomized
controlled trials for inclusion in this review,
and, as a result, there is limited discussion of
methodological weaknesses of the included
studies. We sought to review only the most
methodologically sound studies, but this selection bias should not imply that randomized
controlled trials are beyond criticism, or that
case reports, case series, and open-label trials
are without merit.
CONCLUSIONS
The current state of evidence from randomized controlled clinical trials supports the use
of risperidone and methylphenidate to treat
173
symptoms of aggression and SIB in children
and adolescents with autism and autism spectrum disorders. Several other medications have
been studied using open-label designs and
should be re-examined under placebo-controlled conditions. These medications include
fluoxetine (Fatemi et al. 1998), citalopram (Couturier and Nicolson 2002; Namerow et al. 2003),
escitalopram (Owley et al. 2005), mirtazapine
(Posey et al. 2001), valproate (Hollander et al.
2001), olanzapine (Potenza et al. 1999; Kemner
et al. 2002), and quetiapine (Martin et al. 1999;
Findling et al. 2004). Additional RCTs may produce further evidence to support the use of
these medications and provide a broader arsenal of treatment options for aggression and SIB
in children and adolescents with autism.
Serotonin reuptake inhibitors, in particular,
are a promising target for studies in the future.
A recent RCT of fluoxetine in children with
autism, for example, demonstrated significant
benefit on repetitive behavior and no significant differences as compared to placebo in adverse effects, including agitation (Hollander et
al. 2005a). However, worsening agitation has
been reported across some studies of SSRIs in
the treatment of autism (Fatemi et al. 1998;
Couturier and Nicolson 2002, Namerow et al.
2003; Owley et al. 2005), and this emphasizes
the need to exercise caution and careful monitoring of the use of serotonergic medications in
this patient population. Subject selection criteria will also require careful consideration of the
presence of agitation or mood cycling at baseline. Valproate is likewise deserving of additional RCTs. A recent RCT of valproate for the
prevention of irritability associated with fluoxetine treatment in autism demonstrated significant benefit as compared to placebo (Anagnostou et al. 2006). Future studies of valproate
will require careful consideration of dosing and
blood levels as well as study duration to assess
efficacy. Perhaps higher valproate blood levels
and a longer treatment period will produce significant effects. Additionally, previous work
has shown -adrenergic antagonists, such as
propranolol and nadolol, to have some efficacy
in reducing aggressive behavior in individuals
with mental retardation (Ratey et al. 1986). Because approximately 75% of children with
autism suffer from co-morbid mental retarda-
174
PARIKH ET AL.
tion (Chakrabarti and Fombonne 2001), further
studies should be conducted to determine the
appropriateness of their use in children with
autism.
In general, clinical trials in children and
adolescents with autism should be initiated
with low starting dosages and gradual titration schedules. As with other medications,
benefits (both short-term as well as longterm) must be weighed against risks, and
future research with larger samples and
placebo-controlled designs will aid in that
calculation. Further, future studies, controlled or otherwise, would benefit from systematic assessment of side effects to help clarify safety profiles and differentiate which
medications within certain classes may be
more likely to cause specific side effects. Likewise, improving our understanding of the nature and likelihood of medication side effects
in populations with autism may help identify
risk factors to predict in advance which individuals are most vulnerable.
Several challenges exist to designing valuable clinical trials and remain to be overcome.
It is important to identify target symptoms and
to develop better outcome measures to gauge
improvement (Hollander et al. 2004). Standardized assessments of aggression and SIB,
for instance, should therefore be incorporated
into clinical trials in autism. Trials should also
develop subject inclusion criteria that are realistic and can be generalized to clinical practice
but that select subjects with aggression. Finally,
an important direction for the future is to design studies that evaluate the efficacy and tolerability of these medications over both the
short and long-term.
DISCLOSURES
Mr. Mihir Parikh and Dr. Alexander Kolevzon have no conflicts of interest or financial ties
to disclose. Dr. Hollander receives support
from NIH STAART Center of Excellence grant
#1U54 MH066673-01A1, Orphan Products Division of the Food and Drug Administration
grant #FD-R-001520-01-03, and an investigatorinitiated research grant from Lilly Research
Labs (EH).
REFERENCES
Aman MG: Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol 11:225–228, 2004.
Aman MG, Singh NN, Stewart AW, Field CJ: Psychometric characteristics of the Aberrant Behavior Checklist.
Am J Ment Defic 89:492–502, 1985.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV).
Washington (DC), American Psychiatric Association,
1994.
Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich
MH, Feucht M: Omega-3 fatty acids supplementation
in children with autism: A double-blind randomized,
placebo-controlled pilot study. Biol Psychiatry 61:551–
553, 2007.
Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E: Divalproex versus placebo for the
prevention of irritability associated with fluoxetine
treatment in autism spectrum disorder. J Clin Psychopharmacol 26:444–446, 2006.
Anderson GM, Freedman DX, Cohen DJ, Doe A, Doe B:
Whole blood serotonin in autistic and normal subjects.
J Child Psych Psychiatry 28:885–900, 1987.
Anderson GM, Scahill L, McCracken JT, McDougle CJ,
Aman MG, Tierney E, Arnold LE, Martin A, Katsovich
L, Posey DJ, Shah B, Vitiello B: Effects of short- and
long-term risperidone treatment on prolactin levels in
children with autism. Biol Psychiatry 61:545–550, 2007.
Arnold LE, Vitiello B, McDougle CJ, Scahill L, Shah B,
Gonzalez NM, Chuang S, Davies M, Hollway J, Aman
MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E: Patient-defined target symptoms respond to
risperidone in RUPP Autism Study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42:1443–1450, 2003.
Audenaert K, Laere KV, Dumont F, Siegers G, Mertens J,
Heeringen Cv, Dierckx RA: Decreased frontal serotonin 5-HT receptor binding index in deliberate selfharm patients. Eur J Nuclear Med 28:175–182, 2001.
Baker SM: A biochemical approach to the problem of
dyslexia. J Learn Disabil 18:581–584, 1985.
Barnard L, Young AH, Fearson J, Geddes J, O’Brien G: A
systematic review of the use of atypical antipsychotics
in autism. J Psychopharmacol 16:93–101, 2002.
Bekaroglu M, Aslan Y, Gedik Y, Deger O, Mocan H, Erduran E, Karahan C: Relationships between serum free
fatty acids and zinc, and attention deficit hyperactivity disorder: A research note. J Child Psychol Psychiatry 37:225–227, 1996.
Bell JG, Sargent JR, Tocher DR, Dick JR: Red blood cell
fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 63:21–25, 2000.
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM,
Glen AC: Essential fatty acids and phospholipase A2
in autistic spectrum disorders. Prostoglandins, Leukot,
Essent Fatty Acids 71:201–204, 2004.
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW:
Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism
Dev Disord 31:175–181, 2001.
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten
AF, Kelley AE, Schmeichel B, Hamilton C, Spencer
RC: Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal
cortex at low doses that enhance cognitive function.
Biol Psychiatry 60:1111–1120, 2006.
Birmaher B, Quintana H, Greenhill L: Methylphenidate
treatment of hyperactive autistic children. J AmAcad
Child Adolesc Psychiatry 27:248–251, 1988.
Bouvard MP, Leboyer M, Launay J, Recasens C, Plumet
M, Waller-Perotte D, Tabuteau F, Bondoux D, Dugas
M, Lensing P, Panksepp J: Low-dose naltrexone effects
on plasma chemistries and clinical symptoms in
autism: A double-blind, placebo-controlled study. Psychiatry Res 58:191–201, 1995.
Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein
L: Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes.
Mol Endocrinol 17:1640–1646, 2003.
Burgess JR, Stevens L, Zhang W and Peck L: Long-chain
polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr
71:327S–330S, 2000.
Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M: Naltrexone in autistic children:
Behavioral symptoms and attentional learning. J
Am Acad Child Adolesc Psychiatry 32:1283–1291,
1993.
Carey T, Ratliff-Schaub K, Funk J, Weinle C, Myers M,
Jenks J: Double-blind placebo-controlled trial of secretin: Effects on aberrant behavior in children with
autism. J Autism Dev Disord 32:161–167, 2002.
Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P,
Panerai A: Beta-endorphin levels in peripheral blood
mononuclear cells and long-term naltrexone treatment
in autistic children. European Neuropsychopharmacol
9:361–366, 1999.
Chakrabarti S, Fombonne E: Pervasive developmental
disorders in preschool children. JAMA 285:3093–3099,
2001.
Connor DF, Fletcher KE, Swanson JM: A meta-analysis of
clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry
38:1551–1559, 1999.
Cook EH, Leventhal BL, Heller W, Doe A, Doe B: Autistic children and their first-degree relatives: Relationships between serotonin and norepinephrine levels
and intelligence. J Neuropsychiatry Clin Neurosci
2:268–274, 1990.
Couturier JL, Nicolson R: A retrospective assessment of
citalopram in children and adolescents with pervasive
developmental disorders. J Child Adolesc Psychopharmacol 12:243–248, 2002.
Czapinski P, Blaszczyk B, Czuczwar SJ: Mechanisms of
action of antiepileptic drugs. Curr Top Medicinal
Chem 5:3–14, 2005.
175
Danielsson S, Gillberg IC, Billstedt E, Gillberg C, Olsson
I: Epilepsy in young adults with autism: A prospective
population-based follow-up study of 120 individuals
diagnosed in childhood. Epilepsia 46:918–923, 2005.
Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen
MO, Sunbol MM, Boland J, Hodge A, O’Halloran RA,
Bitter I: Effectiveness of antipsychotic treatments for
schizophrenia: Interim 6-month analysis from a
prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65:312–321, 2004.
Elchaar GM, Maisch NM, Augusto LM, Wehring HJ: Efficacy and safety of naltrexone use in pediatric patients
with autistic disorder. Ann Pharmacother 40:1086–1095,
2006.
Ernst M, Devi L, Silva RR, Gonzalez NM, Small AM, Malone RP, Campbell M: Plasma beta-endorphin levels,
naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 29:221–227, 1993.
Fatemi SH, Realmuto GM, Khan L, Thuras P: Fluoxetine
in treatment of adolescent patients with autism: A longitudinal open trial. J Autism Dev Disord 28:303–307,
1998.
Ferrari PF, van Erp AM, Tornatzky W, Miczek KA: Accumbal dopamine and serotonin in anticipation of the
next aggressive episode in rats. Eur J Neurosci 17:371–378,
2003.
Findling RL: Pharmacological treatment of behavioral
symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 66:26–31, 2005.
Findling RL, Maxwell K, Wiznitzer M: An open clinical
trial of risperidone monotherapy in young children
with autistic disorder. Psychopharmacol Bull 33:155–
159, 1997.
Findling RL, McNamara NK, Gracious BL, O’Riordan
MA, Reed MD, Demeter C, Blumer JL: Quetiapine in
nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287–294, 2004.
Food and Drug Administration: FDA Approves the First
Drug to Treat Irritability Associated with Autism,
Risperdal. FDA News, 2006.
Gilberg C. Endogenous opioids and opiate antagonists in
autism: Brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 37:237–245,
1995.
Gobbi G, Gaudreau PO, Leblanc N: Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J
Clin Psychopharmacol 26:467–473, 2006.
Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein
OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP,
Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn
JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate
doses in children with ADHD: The MTA titration trial.
J Am Acad Child Adolesc Psychiatry 40:180–187, 2001.
Haddad PM and Wieck A: Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and
management. Drugs 64:2291–2314, 2004.
176
Halperin JM, Kalmar JH, Schulz KP, Marks DJ, Sharma
V, Newcom JH: Elevated childhood serotonergic function protects against adolescent aggression in disruptive boys. J Am Acad Child Adolesc Psychiatry
45:833–840, 2006.
Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S: Adverse side effects of Ritalin among mentallyretarded children with ADHD. J Am Acad Child Adolesc Psychiatry 30:241–245, 1991.
Handen BL, Johnson CR, Lubetsky M: Efficacy of
methylphenidate among children with autism and
symptoms of attention-deficit hyperactivity disorder. J
Autism Dev Disord 30:245–255, 2000.
Hanley HG, Stahl SM, Freedman DX, Doe A, Doe B: Hyperserotonemia and amine metabolites in autistic and
retarded children. Arch Gen Psychiatry 34:521–531,
1977.
Harris JC: Resolved: Autistic children should have a trial
of naltrexone. J Am Acad Child Adolesc Psychiatry
35:248–251, 1996.
Hazell PL, Stuart JE: A randomized controlled trial of
clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child
Adolesc Psychiatry 42:886–894, 2003.
Hellings JA, Nickel EJ, Weckbaugh M, McCarter K,
Mosier M, Schroeder SR: The Overt Aggression Scale
for rating aggression in outpatient youth with autistic
disorder: Preliminary findings. The J Neuropsychiatry
Clin Neuroscis 17:29–35, 2005a.
Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone
JR, Reese RM, Hall S, Ermer DJ, Tsai LY, Schroeder SR,
Cook EH: A double-blind, placebo-controlled study of
valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:682–692, 2005b.
Hellings JA, Zarcone JR, Valdovinos MG, Reese RM,
Gaughan E, Schroeder SR: Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc
Psychopharmacol 15:885–892, 2005c.
Hoglund E, Korzan WJ, Watt MJ, Forster GL, Summers
TR, Johannessen HF, Renner KJ, Summers CH: Effects
of L-DOPA on aggressive behavior and central
monoaminergic activity in the lizard Anolis carolinensis, using a new method for drug delivery. Behav Brain
Res 156:53–64, 2005.
Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R,
Novotny S: An open trial of divalproex sodium in
autism spectrum disorders. J Clin Psychiatry 62:530–
534, 2001.
Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny
S, Wasserman S, Iyengar R: A placebo controlled
crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacol 30:582–589, 2005a.
Hollander E, Phillips A, King BH, Guthrie D, Aman MG,
Law P, Owley T and Robinson R: Impact of recent findings on study design of future autism clinical trials.
CNS Spectr 9: 49-56, 2004.
PARIKH ET AL.
Hollander E, Phillips AT and Yeh C: Targeted treatments
for symptom domains in child and adolescent autism.
Lancet 362:732–734, 2003a.
Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy
SL, Wozniak P, Sommerville KW, Nemeroff CB: Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacol 28:1186–1197, 2003b.
Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB:
Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162:621–624, 2005b.
Horvath K, Perman JA: Autism and gastrointestinal
symptoms. Current Gastroenterol Rep 4:251–258, 2002.
Horvath K, Stefanatos G, Sokoslski KN, Wachtel R,
Nabors L, Tildon JT: Improved social and language
skills after secretin administration in patients with
autistic spectrum disorders. J Assoc Acad Minority
Physicians 9:9–15, 1998.
Hoshino Y, Kumashiro H, Kanero M, Takahashi Y: The
effects of methylphenidate in early infantile autism and
its relation to serum serotonin levels. Folia Psyciatrica
et Neurologica Japonica 31:605–614, 1977.
Ihalainen JA, Tanila H: In vivo regulation of dopamine
and noradrenaline release by alpha2A-adrenoceptors
in the mouse nucleus accumbens. J Neurochem
91:49–56, 2004.
Imamura M, Lee KY, Song Y, Moriyasu M, Chang TM,
Chey WY: Role of secretin in negative feedback regulation of postprandial pancreatic secretion in dogs.
Gastroenterology 105:548–553, 1993.
Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children
with autistic disorder. J Clin Psychopharmacol
12:322–327, 1992.
Johansson AK, Bergvall AH, Hansen S: Behavioral disinhibition following basal forebrain excitotoxin lesions:
Alcohol consumption, defensive aggression, impulsivity, and serotonin levels. Behav Brain Res 102:17–29,
1999.
Kemner C, Willemsen-Swinkels SH, DeJonge M, Tuynman-Qua J, vanEngeland H: Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455–460, 2002.
Kern JK, Miller VS, Evans PA, Trivedi MH: Efficacy of
porcine secretin in children with autism and pervasive
developmental disorder. J Autism Dev Disord
32:153–160, 2002.
King BH: Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord
30:439–445, 2000.
Kolevzon A, Mathewson KA, Hollander E: Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. J Clin Psychiatry 67:407–414,
2006.
Leboyer M, Philippe A, Bouvard M, Doe A, Doe B: Whole
blood serotonin and plasma beta-endorphin in autistic
probands and their first-deree relatives. Biol Psychiatry 45:158–163, 1999.
PSYCHOPHARMACOLOGY OF AGGRESSION IN AUTISM
Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI,
Cohen DJ: Clonidine treatment of Gilles de la
Tourette’s syndrome. Arch Gen Psychiatry 48:324–328,
1991.
Leventhal BL, Cook EH, Morford M, Doe A, Doe B: Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord
20:499–511, 1990.
MacDonell LE, Skinner FK, Ward PE, Glen AI, Glen AC,
Macdonald DJ, Boyle RM, Horrobin DF: Increased levels of cytosolic phospholipase A2 in dyslexics. Prostaglandins Leukot Essent Fatty Acids 63:37–39, 2000.
Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study.
Diabetologia 48:215–221, 2005.
Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA: Risperidone treatment in children and adolescents with autism: Short- and long-term safety and
effectiveness. J Am Acad Child Adolesc Psychiatry
41:140–147, 2002.
Malone RP, Gratz SS, Delaney MA, Hyman SB: Advances
in drug treatments for children and adolescents with
autism and other pervasive developmental disorders.
CNS Drugs 19: 923–934, 2005.
Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents
with autistic disorder. J Child Adolesc Psychopharmacol 9:99–107, 1999.
Martin A, Koenig K, Anderson GM, Scahill L: Low-dose
fluvoxamine treatment of children and adolescents
with pervasive developmental disorders: A prospective, open-label study. J Autism Dev Disord 33:77–85,
2003.
Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive
developmental disorders treated with risperidone. J
Clin Psychiatry 64:1039–1047, 2003.
McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK,
Heninger GR, Price LH: Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch
Gen Psychiatry 53:993–1000, 1996a.
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR,
Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001–1008, 1996b.
McDougle CJ, Stigler KA, Posey DJ: Treatment of aggression in children and adolescents with autism and
conduct disorder. J Clin Psychiatry 64:16–25, 2003.
Mitchell EA, Aman MG, Turbott SH, Manku M: Clinical
characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 26:406–411, 1987.
Molina V, Ciesielski L, Gobaille S, Mandel P: Effects of
the potentiation of the GABAergic neurotransmission
in the olfactory bulbs on mouse-killing behavior. Pharmacol Biochem Behav 24:657–664, 1986.
Molloy CA, Manning-Courtney P, Swayne S, Bean J,
Brown JM, Murray DS, Kinsman AM, Brasington M,
Ulrich CD: Lack of benefit of intravenous synthetic hu-
177
man secretin in the treatment of autism. J Autism Dev
Disord 32:545–551, 2002.
Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux
MC: Use of citalopram in pervasive developmental disorders. Devel Behav Pediatr 24:104–108, 2003.
Niederhofer H, Staffen W, Mair A: Tianeptine: A novel
strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacol
18:389–393, 2003.
Owley T, McMahon W, Cook EH, Laulhere T, South M,
Mays LZ, Shernoff ES, Lainhart J, Modahl CB, Corsello
C, Ozonoff S, Risi S, Lord C, Leventhal BL, Filipek PA:
Multisite, double-blind, placebo-controlled trial of
porcine secretin in autism. J Am Acad Child Adolesc
Psychiatry 40:1293–1299, 2001.
Owley T, Walton L, Salt F, Guter SJ, Winnega M, Leventhal BL, Cook EH: An open-label trial of escitalopram
in pervasive developmental disorders. J AmAcad
Child Adolesc Psychiatry 44:343–348, 2005.
Patel NC, Crismon ML, Hoagwood K, Jensen PS: Unanswered questions regarding atypical antipsychotic use
in aggressive children and adolescents. J Child Adolesc Psychopharmacol 15:270–284, 2005.
Physicians’ Desk Reference. Montvale (New Jersey),
Thomson Healthcare, 2006.
Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle
CJ: A naturalistic open-label study of mirtazapine in
autistic and other pervasive developmental disorders.
J Child Adolesc Psychopharmacol 11:267–277, 2001.
Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults
with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 19:37–44, 1999.
Quintana H, Birmaher B, Stedge D, Lennon S, Freed J,
Bridge J, Greenhill L: Use of methylphenidate in the
treatment of children with autistic disorder. J Autism
Dev Disord 25:283–294, 1995.
Rappaport N, Thomas C: Recent reseach findings on aggressive and violent behavior in youth: Implications
for clinical assessment and intervention. J Adolesc
Health 35:260–277, 2004.
Ratey JJ, Mikkelsen EH, Smith GB, Upadhyaya A, Zuckerman HS, Martell D, Sorgi P, Polakoff S, Bemporad J:
Beta-blockers in the severely and profoundly mentally
retarded. J Clin Psychopharmacol 6:103–107, 1986.
Remington G, Sloman L, Konstantareas M, Parker K, Gow
R: Clomipramine versus haloperidol in the treatment
of autistic disorder: A double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21:
440–444, 2001.
Retz W, Rosler M, Supprian T, Retz-Junginger P, Thome J:
Dopamine D3 receptor gene polymorphism and violent
behavior: relation to impulsiveness and ADHD-related
psychopathology. J Neural Transm 110:561–572, 2003.
Ritvo ER, Yuwiler A, Geller E, Doe A, Doe B: Increased
blood serotonin and platelets in early infantile autism.
Arch Gen Psychiatry 23:566–572, 1970.
Rothenberger A: Psychopharmacological treatment of
self-injurious behavior in individuals with autism.
Acta Paedopsychiatrica 56:99–104, 1993.
178
RUPP: Risperidone in children with autism and serious
behavioral problems. N Engl J Med 347:314–321, 2002.
RUPP: Randomized, controlled, crossover trial of
methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266–
1274, 2005a.
RUPP: Risperidone treatment of autistic disorder: Longerterm benefits and blinded discontinuation after 6
months. Amer J Psychiatry 162:1361–1369, 2005b.
Sandman CA: B-endorphin disregulation in autistic and
self-injurious behavior: A neurodevelopmental hypothesis. Synapse 2:193–199, 1988.
Sandman CA, Hetrick W, Taylor DV and Chicz-DeMet A:
Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. Am
J Ment Retard 102:182–199, 1997.
Sandman CA, Hetrick W, Taylor D and Marion S: Uncoupling of proopiomelanocortin (POMC) fragments is
related to self-injury. Peptides 21:785–791, 2000.
Sandyk R and Bamford CR: Deregulation of hypothalamic dopamine and opioid activity and the pathophysiology of self-mutilatory behavior in Tourette’s syndrome. J Clin Psychopharmacol 7:367, 1987.
Schain RJ and Freedman DX: Studies on 5-hydroxyindole
metabolism in autistic and other mentally retarded
children. J Pediatr 58:315–320, 1961.
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens
M, Swyzen W, De Smedt G: Risperidone and haloperidol in first-episode psychosis: A long-term randomized
trial. Am J Psychiatry 162:947–953, 2005.
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I,
Dunbar F: Risperidone in the treatment of disruptive
behavioral symptoms in children with autistic and
other pervasive developmental disorders. Pediatr
114:e634–e641, 2004.
Sival RC, Duivenvoorden HJ, Jansen PA, Haffmans PM,
Duursma SA, Eikelenboom P: Sodium valproate in aggressive behaviour in dementia: A twelve-week open
label follow-up study. Int J Geriatr Psychiatry 19: 305312, 2004.
Soderpalm B: Anticonvulsants: Aspects of their mechanism of action. Eur J Pain 6 (Suppl A): 3–9, 2002.
Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez
A: Comparison of clonidine response in the treatment
of attention-deficit hyperactivity disorder with and
without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 32:350–353, 1993.
Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA,
Lipp SR, Burgess JR: Essential fatty acid metabolism in
boys with attention-deficit hyperactivity disorder. Am
J Clin Nutr 62:761–768, 1995.
Stevens LJ, Zentall SS, Abate ML, Kuczek T, Burgess JR:
Omega-3 fatty acids in boys with behavior, learning,
and health problems. Physiol Behav 59:915–920, 1996.
Stockton ME, Rasmussen K: Electrophysiological effects
of olanzapine, a novel atypical antipsychotic, on A9
and A10 dopamine neurons. Neuropsychopharmacol
14:97–105, 1996.
Stodgell CJ, Loupe PS, Schroeder SR, Tessel RE: Crosssensitization between footshock stress and apomor-
View publication stats
PARIKH ET AL.
phine on self-injurious behavior and neostriatal catecholamines in a rat model of Lesch-Nyhan syndrome.
Brain Res 783:10–18, 1998.
Strayhorn JM, Rapp N, Donina W, Strain PS: Randomized
trial of methylphenidate for an autistic child. J Amer
Acad Child Adolesc Psychiatry 27:244–247, 1988.
Sweetman S (ed.): Martindale: The Complete Drug Reference. London (UK), Pharmaceutical Press, 2004.
Takahashi S, Kanai H, Miyamoto Y, Doe A, Doe B: Reassessment of elevated serotonin levels in blood
platelets in early infantile autism. J Autism Childhood
Schizophrenia 6:317–326, 1976.
Toichi M, Kamio Y: Paradoxical autonomic response to
mental tasks in autism. J Autism Dev Disord 33:417–
426, 2003.
Troost PW, Lahuis BF, Steenhuis M, Ketelaars CE, Buitelaar JK, VanEngeland H, Scahill L, Minderaa RB, Hoekstra PJ: Long-term effects of risperidone in children
with autism spectrum disorders: A placebo discontinuation study. J Am Acad Child Adolesc Psychiatry
44:1137–1144, 2005.
Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J,
Gabriels R, Abbott RD, Dawson G: A randomized, double-blind, placebo-controlled trial of porcine versus
synthetic secretin for reducing symptoms of autism. J
Am Acad Child Adolesc Psychiatry 41:1315–1321, 2002.
Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C, Chalon S: Plasma
fatty acid levels in autistic children. Prostaglandins
Leukot Essent Fatty Acids 65:1–7, 2001.
Vergnes M, Depaulis A, Boehrer A, Kempf E: Selective increase of offensive behavior in the rat following intrahypothalamic 5,7-DHT-induced serotonin depletion. Behav Brain Res 29:85–91, 1988.
Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E: Levetiracetam versus placebo in childhood and adolescent
autism: A double-blind placebo-controlled study. Int
Clin Psychopharmacol 21:363–367, 2006.
Willemsen-Swinkels SH, Buitelaar JK, vanEngeland H:
The effects of chronic naltrexone treatment in young
autistic children: A double-blind placebo-controlled
study. Biol Psychiatry 39:1023–1031, 1996.
Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG and
vanEngeland H: Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry
Res 58:203–215, 1995.
Zingarelli G, Ellman G, Hom A, Wymore M, Heidorn S,
Chicz-DeMet A: Clinical effects of naltrexone on autistic behavior. Amer J Ment Retard 97:57–63, 1992.
Address reprint requests to:
Alexander Kolevzon, M.D.
Mount Sinai School of Medicine
Department of Psychiatry
One Gustave L.Levy Place, Box 1230
New York, NY 10029
E-mail: alexander.kolevzon@mssm.edu